FDA Advancements in HER2+ Breast Cancer

For patients with ER-positive breast cancer who remain premenopausal—or regain ovarian function—following chemotherapy, 2 years of ovarian suppression may be beneficial.

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

Stronger interventions are needed to improve adjuvant treatment rates among breast cancer survivors.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Subcutaneous trastuzumab demonstrated a safety profile that is consistent with the known profile with intravenous administration.

At median follow up of 33.6 months, patients who received the triplet combination of tucatinib, letrozole, and palbociclib, experienced a median progression-free survival of 8.4 months.